Evolus, Inc. (NASDAQ:EOLS) Insider Sells $24,434.20 in Stock

Evolus, Inc. (NASDAQ:EOLS) insider Rui Avelar sold 2,252 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $10.85, for a total value of $24,434.20. Following the sale, the insider now directly owns 366,595 shares in the company, valued at $3,977,555.75. This trade represents a 0.61 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Evolus Trading Up 4.6 %

NASDAQ:EOLS traded up $0.50 on Thursday, reaching $11.35. The stock had a trading volume of 541,978 shares, compared to its average volume of 588,928. Evolus, Inc. has a 12-month low of $9.80 and a 12-month high of $17.82. The company has a market cap of $718.69 million, a price-to-earnings ratio of -12.47 and a beta of 1.27. The firm’s fifty day moving average is $13.56 and its two-hundred day moving average is $13.75. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.

Institutional Investors Weigh In On Evolus

Institutional investors have recently bought and sold shares of the stock. Caligan Partners LP increased its holdings in shares of Evolus by 1.2% during the 3rd quarter. Caligan Partners LP now owns 2,193,488 shares of the company’s stock worth $35,535,000 after buying an additional 25,698 shares during the last quarter. Geode Capital Management LLC raised its holdings in Evolus by 0.9% in the third quarter. Geode Capital Management LLC now owns 1,210,621 shares of the company’s stock valued at $19,616,000 after buying an additional 11,027 shares during the period. Lord Abbett & CO. LLC lifted its position in Evolus by 23.4% during the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock valued at $16,126,000 after buying an additional 188,685 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Evolus by 0.9% during the third quarter. Assenagon Asset Management S.A. now owns 955,555 shares of the company’s stock valued at $15,480,000 after buying an additional 8,452 shares in the last quarter. Finally, Rice Hall James & Associates LLC grew its stake in Evolus by 6.3% during the third quarter. Rice Hall James & Associates LLC now owns 904,900 shares of the company’s stock worth $14,659,000 after buying an additional 53,605 shares during the period. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on EOLS. HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of Evolus in a report on Thursday, November 7th. Barclays boosted their target price on Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a research report on Monday, September 16th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Friday, September 13th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.